Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients

Radiation Medicine - Medical Imaging and Radiation Oncology

Volumn 23, Issue 3, 2005, Pages 189-194

  Kariya, Shinji ^a   Ogawa, Yasuhiro ^a   Nishioka, Akihito ^a   Moriki, Toshiaki ^b   Ohnishi, Takenao ^a   Ito, Satoshi ^a   Murata, Yoriko ^a   Yoshida, Shoji ^a  

^a KOCHI UNIVERSITY   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Antitumor effect; Breast cancer; Gene expression; Neoadjuvant chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PIRARUBICIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE NEU; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; ULTRASOUND;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 21044432904     PISSN: 02882043     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Esteva FJ, Hortobagyi GN. Locally advanced breast cancer. Hematol Oncol Clin North Am, 13: 457-472, 1999.
2. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol, 17: 460-469, 1999.
3. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol, 15: 2483-2493, 1997.
4. Pierga JY, Mouret E, Laurence V, et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. The role of clinical response. Eur J Cancer, 39: 1089-1096, 2003.
5. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer, 86: 1041-1046, 2002.
6. Wenger CR, Beardslee S, Owens MA, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat, 28: 9-20, 1993.
7. Gasparini G, Bevilacqua P, Boracchi P, et al. Prognostic value of p53 expression in early-stage breast carcinoma compared with tumour angiogenesis, epidermal growth factor receptor, c-erbB-2, cathepsin D, DNA ploidy, parameters of cell kinetics and conventional features. Int J Oncol, 4: 155-162, 1994.
8. Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer, 74: 433-437, 1997.
9. Veronese SM, Maisano C, Scibilia J. Comparative prognostic value of Ki-67 and MIB-1 proliferation induces in breast cancer. Anticancer Res, 15: 2717-2722, 1995.
10. Railo M, Nordling S, von Boguslawsky K, et al. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer, 68: 579-583, 1993.
11. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P. Proliferation index as a prognostic marker in breast cancer. Cancer, 71: 3926-3931, 1993.
12. Railo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K, Nordling S. Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol, 36: 369-374, 1997.
13. Pierga JY, Leroyer A, Viehl P, Mosseri V, Chevillard S, Magdelenat H. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat, 37: 57-64, 1996.
14. Jensen V, Ladekarl M, Holm Nielsen P, Meisen F, Sorensen FB. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node negative breast cancer. J Pathol, 176: 343-352, 1995.
15. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst, 90: 1601-1608, 1998.
16. Layfield LJ, Gupta D, Mooney EE. Assessment of Tissue Estrogen and Progesterone Receptor Levels: A Survey of Current Practice, Techniques, and Quantitation Method. Breast J, 6: 189-196, 2000.
17. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palmer P. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol, 98: 408-418, 1992.
18. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer, 40: 205-211, 2004.
19. Penault-Llorca F, Cayre A, Bouchet Mishellany F, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol, 22: 1319-1325, 2003.
20. Barbareschi M, Caffo O, Veronese S, et al. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol, 27: 1149-1155, 1996.
21. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244: 707-712, 1989.
22. Wang J, Buchholz TA, Middleton LP, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer, 94: 3107-3114, 2002.
23. Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer, 88: 406-412, 2003.
24. Aas T, Geisler S, Eide GE, et al. Predictive value of tumor cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer, 39: 438-446, 2003.
25. Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer, 84: 129-134, 1999.
26. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res, 8: 1061-1067, 2002.
27. Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer, 97: 1758-1765, 2003.
28. Vincent-Salomon A, Carton M, Freneaux P, et al. ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer, 36: 586-591, 2000.
29. MacGrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer, 74: 1458-1465, 1996.
30. Petit T, Borel C, Ghnassia J-P, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res, 7: 1577-1581, 2001.
31. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol, 133: 1710-1715, 1984.
32. Daidone MG, Veneroni S, Benini E, et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer, 84: 580-586, 1999.